🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

The sexually transmitted infection are increasing globally, with data suggesting over 82 million instances each year. Particularly high rates are reported in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of growing infection rates, the spread of superbugs and the very limited therapeutic options at this time.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The global health body has listed it as a "critical concern". A tracking program found that resistance to key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Therapies Receive Authorization

Zoliflodacin, also known as Nuzolvence, was authorized by the American regulatory agency in mid-December for treating gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, gained clearance in concurrent days. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a unique collaborative effort for drug creation. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This approval represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per findings detailed in a prominent scientific publication, the new drug cured more than 90% of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which uses an injection and a pill. The study enrolled hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to license and sell the drug in numerous developing nations.

Medical professionals directly involved have shared positive views. Access to a easy-to-administer therapy like this is described as a "critical tool" for public health efforts. This is viewed as essential to alleviate the strain of the illness for people and to halt the transmission of extremely resistant gonorrhoea globally.